Expert view: ddPCR whole cell DNA workflow efficiently measures success of CAR T-cell production
Posted: 10 September 2020 | Bio-Rad Laboratories | No comments yet
Not every step of CAR T-cell manufacturing can be tightly regulated, introducing some significant quality control challenges for companies developing CAR T cancer therapies
For example, when scientists transduce a population of T cells with the CAR gene using the virus, the transduction of the gene into the genome needs to be at a level that it does not have too many or too few events. Knowing the percent transduction efficiency of the cells helps ensure that the treatment is safe and effective.
Related topics
Flow Cytometry, Gene Therapy, Genomics, T cells
Related organisations
Bio-Rad Laboratories